Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you. Given that this is already the middle of the week and we have survived this far, no reason not to continue, yes? Just consider the alternatives. In fact, this modest accomplishment calls for celebration. So please join us in quaffing a ritual cup of needed stimulation. Or grab a bottle of water, if you prefer. Meanwhile, here are a few items of interest to help you along. Once again, we hope you have a successful day and, of course, keep in touch. We enjoy hearing your tips and tidbits. …

Catalent (CTLT), a contract drug manufacturer, is planning a major expansion of its Covid-19 vaccine production in Europe, enabling it to make more doses of the Johnson & Johnson (JNJ) shot, The Wall Street Journal reports. Catalent will bring online a second J&J vaccine production line at its plant in Anagni, Italy, during the fourth quarter. The expansion has the potential to double the plant’s output of Covid-19 vaccines and should help boost Covid-19 vaccine supplies in the European Union.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • May one observe a certain irony in that Catalent is part of the J&J vaccine domestic US production chain that is NOT delivering as expected – but is planning to expand in Europe? Hmmm ….

Comments are closed.